Practical Considerations in Delivering CAR T Cell Therapies in Singapore by Dr Chen Yun Xin
5 July 2021
CAR T-cell therapy is transforming blood cancer treatment, but delivering it outside clinical trials comes with real challenges. Find out what it takes to build the infrastructure and meet the steps needed to make this therapy available to patients.
Chimeric Antigen Receptor (CAR) T-cell therapy is changing the treatment landscape of haematological malignancies. As these treatments gain regulatory approvals and become an available option to patients meeting disease indications, administrative and logistical challenges in delivering CAR therapy outside of clinical trials have also emerged.
The success of CAR T-cell therapy has brought about much media attention and has led to tremendous excitement. Patients may also assume there will be broad access to cellular therapeutics in a similar fashion as other chemotherapeutic agents. However, there are challenges to make these truly available to them. The process of building cell therapy infrastructure, meeting regulatory requirements, and treating patients with CAR T-cell therapy require significant planning and coordination.
